Dual-Stimuli-Responsive Gut Microbiota-Targeting Nitidine Chloride-CS/PT-NPs Improved Metabolic Status in NAFLD

References

• Mouries J, Brescia P, Silvestri A, et al. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development. J Hepatol. 2019;71(6):1216–1228. doi:10.1016/j.jhep.2019.08.005
   PubMed Web of Science ®Google Scholar
• Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009;49(6):1877–1887. doi:10.1002/hep.22848
   PubMed Web of Science ®Google Scholar
• Murata Y, Mizuno S, Kato H, et al. Nonalcoholic steatohepatitis (NASH) after pancreaticoduodenectomy: association of pancreatic exocrine deficiency and infection. Clin J Gastroenterol. 2011;4(4):242–248. doi:10.1007/s12328-011-0226-9
   PubMedGoogle Scholar
• Le MH, Yeo YH, Li X, et al. 2019 global NAFLD prevalence: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022;20(12):2809–2817.e2828. doi:10.1016/j.cgh.2021.12.002
   PubMed Web of Science ®Google Scholar
• Zhou J, Zhou F, Wang W, et al. Epidemiological Features of NAFLD From 1999 to 2018 in China. Hepatology. 2020;71(5):1851–1864. doi:10.1002/hep.31150
   PubMed Web of Science ®Google Scholar
• Sodum N, Kumar G, Bojja SL, Kumar N, Rao CM. Epigenetics in NAFLD/NASH: targets and therapy. Pharmacol Res. 2021;167:105484. doi:10.1016/j.phrs.2021.105484
   PubMed Web of Science ®Google Scholar
• Rong L, Zou J, Ran W, et al. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). Front Endocrinol. 2022;13:1087260. doi:10.3389/fendo.2022.1087260
   PubMedGoogle Scholar
• Boursier J, Mueller O, Barret M, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016;63(3):764–775. doi:10.1002/hep.28356
   PubMed Web of Science ®Google Scholar
• Loomba R, Seguritan V, Li W, et al. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab. 2017;25(5):1054–1062.e1055. doi:10.1016/j.cmet.2017.04.001
   PubMed Web of Science ®Google Scholar
• Alferink LJM, Radjabzadeh D, Erler NS, et al. Microbiomics, metabolomics, predicted metagenomics, and hepatic steatosis in a population-based study of 1355 adults. Hepatology. 2021;73(3):968–982. doi:10.1002/hep.31417
   PubMed Web of Science ®Google Scholar
• Hong Y, Xu WQ, Feng J, et al. Nitidine chloride induces cardiac hypertrophy in mice by targeting autophagy-related 4B cysteine peptidase. Acta Pharmacol Sin. 2023;44(3):561–572. doi:10.1038/s41401-022-00968-6
   PubMed Web of Science ®Google Scholar
• Chen YW. Pharmacokinetic and Pharmacodynamic Study of Nitidine Chloride Solid Lipid Nanoparticles. Guangxi Medical University; 2010.
   Google Scholar
• Zhao S, Jiang L, Mu YN, et al. Study on intestinal absorption of nitidine chloride. Chin Med Mod Dist Educ China. 2018;16(10):96–97+105.
   Google Scholar
• Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101–124. doi:10.1038/s41573-020-0090-8
   PubMed Web of Science ®Google Scholar
• Hoshyar N, Gray S, Han H, Bao G. The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction. Nanomedicine. 2016;11(6):673–692. doi:10.2217/nnm.16.5
   PubMed Web of Science ®Google Scholar
• Wu P, Han J, Gong Y, Liu C, Yu H, Xie N. Nanoparticle-based drug delivery systems targeting tumor microenvironment for cancer immunotherapy resistance: current advances and applications. Pharmaceutics. 2022;14(10):1990. doi:10.3390/pharmaceutics14101990
   PubMed Web of Science ®Google Scholar
• Li S, Zhang H, Chen K, et al. Application of chitosan/alginate nanoparticle in oral drug delivery systems: prospects and challenges. Drug Delivery. 2022;29(1):1142–1149. doi:10.1080/10717544.2022.2058646
   PubMed Web of Science ®Google Scholar
• Chen S, Zhu H, Luo Y. Chitosan-based oral colon-specific delivery systems for polyphenols: recent advances and emerging trends. J Mat Chem B. 2022;10(37):7328–7348. doi:10.1039/D2TB00874B
   PubMed Web of Science ®Google Scholar
• Guo -H-H, Ma C, Zheng W-S, et al. Dual-stimuli-responsive gut microbiota-targeting berberine-CS/PT-NPs improved metabolic status in obese hamsters. Adv Funct Mater. 2020;30(13):1910337. doi:10.1002/adfm.201910337
   Web of Science ®Google Scholar
• Li Y, Zhao D, Qian M, et al. Amlodipine, an anti-hypertensive drug, alleviates non-alcoholic fatty liver disease by modulating gut microbiota. Br J Pharmacol. 2022;179(9):2054–2077. doi:10.1111/bph.15768
   PubMed Web of Science ®Google Scholar
• Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: pathophysiological basis for therapy. J Hepatol. 2020;72(3):558–577. doi:10.1016/j.jhep.2019.10.003
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yang L, Zhao N, et al. Soluble polysaccharide derived from laminaria japonica attenuates obesity-related nonalcoholic fatty liver disease associated with gut microbiota regulation. Mar Drugs. 2021;19(12):699. doi:10.3390/md19120699
   PubMed Web of Science ®Google Scholar
• Zhu X, Cai J, Wang Y, et al. A high-fat diet increases the characteristics of gut microbial composition and the intestinal damage associated with non-alcoholic fatty liver disease. Int J Mol Sci. 2023;24(23):16733. doi:10.3390/ijms242316733
   PubMed Web of Science ®Google Scholar
• Xu J, Bjursell MK, Himrod J, et al. A genomic view of the human-Bacteroides thetaiotaomicron symbiosis. Science. 2003;299(5615):2074–2076. doi:10.1126/science.1080029
   PubMed Web of Science ®Google Scholar
• Zhang C, Zhang M, Pang X, et al. Structural resilience of the gut microbiota in adult mice under high-fat dietary perturbations. ISME J. 2012;6(10):1848–1857. doi:10.1038/ismej.2012.27
   PubMed Web of Science ®Google Scholar
• Safari Z, Gérard P. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD). Cell Molec Life Sci. 2019;76(8):1541–1558. doi:10.1007/s00018-019-03011-w
   PubMed Web of Science ®Google Scholar
• Che Q, Luo T, Shi J, et al. Mechanisms by which traditional Chinese medicines influence the intestinal flora and intestinal barrier. Front Cell Infect Microbiol. 2022;12:863779. doi:10.3389/fcimb.2022.863779
   PubMed Web of Science ®Google Scholar
• Li X, Wu D, Niu J, et al. Intestinal flora: a pivotal role in investigation of traditional Chinese medicine. Am J Chin Med. 2021;49(2):237–268. doi:10.1142/S0192415X21500130
   PubMedGoogle Scholar
• Hamman JH. Chitosan based polyelectrolyte complexes as potential carrier materials in drug delivery systems. Mar Drugs. 2010;8(4):1305–1322. doi:10.3390/md8041305
   PubMed Web of Science ®Google Scholar
• Prandi B, Baldassarre S, Babbar N, et al. Pectin oligosaccharides from sugar beet pulp: molecular characterization and potential prebiotic activity. Food Funct. 2018;9(3):1557–1569. doi:10.1039/C7FO01182B
   PubMed Web of Science ®Google Scholar
• Tang D. Chitosan Improves Obesity by Regulating Intestinal Microbiota and Leptin Levels. Shandong University; 2020.
   Google Scholar
• Bao LK. Characterization of chitosan/pectin polyelectrolyte complex and study of bovine serum protein loading; 2014.
   Google Scholar
• Shaabani E, Sharifiaghdam M, De Keersmaecker H, et al. Layer by layer assembled chitosan-coated gold nanoparticles for enhanced siRNA delivery and silencing. Int J Mol Sci. 2021;22(2):831. doi:10.3390/ijms22020831
   PubMed Web of Science ®Google Scholar
• Fan Z, Wang C, Yang T, et al. Coffee peel extracts ameliorate non-alcoholic fatty liver disease via a fibroblast growth factor 21-adiponectin signaling pathway. Food Funct. 2022;13(13):7251–7259. doi:10.1039/D2FO00081D
   PubMed Web of Science ®Google Scholar
• Jiang J, Yan L, Shi Z, Wang L, Shan L, Efferth T. Hepatoprotective and anti-inflammatory effects of total flavonoids of Qu Zhi Ke (peel of Citrus changshan-huyou) on non-alcoholic fatty liver disease in rats via modulation of NF-κB and MAPKs. Phytomedicine. 2019;64:153082. doi:10.1016/j.phymed.2019.153082
   PubMed Web of Science ®Google Scholar
• Tilg H, Moschen AR, Szabo G. Interleukin-1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology. 2016;64(3):955–965. doi:10.1002/hep.28456
   PubMed Web of Science ®Google Scholar
• Tiegs G, Horst AK. TNF in the liver: targeting a central player in inflammation. Semin Immunopathol. 2022;44(4):445–459. doi:10.1007/s00281-022-00910-2
   PubMed Web of Science ®Google Scholar
• Zhang X, Coker OO, Chu ES, et al. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites. Gut. 2021;70(4):761–774. doi:10.1136/gutjnl-2019-319664
   PubMed Web of Science ®Google Scholar
• Kuang J, Wang J, Li Y, et al. Hyodeoxycholic acid alleviates non-alcoholic fatty liver disease through modulating the gut-liver axis. Cell Metab. 2023;35(10):1752–1766.e1758. doi:10.1016/j.cmet.2023.07.011
   PubMed Web of Science ®Google Scholar
• Xu Y, Wang N, Tan HY, et al. Panax notoginseng saponins modulate the gut microbiota to promote thermogenesis and beige adipocyte reconstruction via leptin-mediated AMPKα/STAT3 signaling in diet-induced obesity. Theranostics. 2020;10(24):11302–11323. doi:10.7150/thno.47746
   PubMed Web of Science ®Google Scholar
• Tremaroli V, Bäckhed F. Functional interactions between the gut microbiota and host metabolism. Nature. 2012;489:7415):242–249. doi:10.1038/nature11552
   Web of Science ®Google Scholar
• Murphy EA, Velazquez KT, Herbert KM. Influence of high-fat diet on gut microbiota: a driving force for chronic disease risk. Curr Opin Clin Nutr Metab Care. 2015;18(5):515–520. doi:10.1097/MCO.0000000000000209
   PubMed Web of Science ®Google Scholar
• Lelouvier B, Servant F, Païssé S, et al. Changes in blood microbiota profiles associated with liver fibrosis in obese patients: a pilot analysis. Hepatology. 2016;64(6):2015–2027. doi:10.1002/hep.28829
   PubMed Web of Science ®Google Scholar
• Hui D, Liu L, Azami NLB, et al. The spleen-strengthening and liver-draining herbal formula treatment of non-alcoholic fatty liver disease by regulation of intestinal flora in clinical trial. Front Endocrinol. 2022;13:1107071. doi:10.3389/fendo.2022.1107071
   PubMed Web of Science ®Google Scholar
• Kirk KF, Nielsen HL, Thorlacius-Ussing O, Nielsen H. Optimized cultivation of Campylobacter concisus from gut mucosal biopsies in inflammatory bowel disease. Gut Pathog. 2016;8:27. doi:10.1186/s13099-016-0111-7
   PubMed Web of Science ®Google Scholar
• Liu F, Lee H, Lan R, Zhang L. Zonula occludens toxins and their prophages in Campylobacter species. Gut Pathog. 2016;8:43. doi:10.1186/s13099-016-0125-1
   PubMed Web of Science ®Google Scholar
• Konikoff T, Gophna U. Oscillospira: a central, enigmatic component of the human gut microbiota. Trends in Microbiol. 2016;24(7):523–524. doi:10.1016/j.tim.2016.02.015
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Betrapally NS, Hylemon PB, et al. Gut microbiota alterations can predict hospitalizations in cirrhosis independent of diabetes mellitus. Sci Rep. 2015;5:18559. doi:10.1038/srep18559
   PubMed Web of Science ®Google Scholar
• Zhuang P, Li H, Jia W, et al. Eicosapentaenoic and docosahexaenoic acids attenuate hyperglycemia through the microbiome-gut-organs axis in db/db mice. Microbiome. 2021;9(1):185. doi:10.1186/s40168-021-01126-6
   PubMed Web of Science ®Google Scholar
• Zeng SL, Li SZ, Xiao PT, et al. Citrus polymethoxyflavones attenuate metabolic syndrome by regulating gut microbiome and amino acid metabolism. Sci Adv. 2020;6(1):eaax6208. doi:10.1126/sciadv.aax6208
   PubMed Web of Science ®Google Scholar
• Liao J, Cao Y, Zhao J, et al. Aqueous extract of Polygala japonica Houtt. ameliorated nonalcoholic steatohepatitis in mice through restoring the gut microbiota disorders and affecting the metabolites in feces and liver. Phytomedicine. 2023;118:154937. doi:10.1016/j.phymed.2023.154937
   PubMed Web of Science ®Google Scholar